Chi phí hiệu quả của trình tự điều trị khởi đầu với afatinib so với osimertinib trong điều trị ung thư phổi không tế bào nhỏ có đột biến EGFR tại Việt Nam

To evaluate the cost-effectiveness of sequential treatment with first-line Afatinib versus Osimertinib in the treatment of non-small cell lung cancer with EGFR mutation in Vietnam. Methods: The decision tree model was built to estimate the cost-effectiveness of two treatment sequences, applying the payer's perspective. Clinical efficacy parameters are compiled from published clinical trials to estimate progression-free survival and treatment costs of each treatment line. Treatment cost parameters and adverse event management are collected based on clinical expert consultation. Results: The sequential treatment with first-line Afatinib had a greater mean time on treatment than that of Osimertinib, at 29.2 months and 24.8 months, respectively. Compared to the sequential treatment with first-line Osimertinib, the sequential treatment with first-line Afatinib is cost-effective. Conclusion: The sequential treatment with first-line Afatinib is cost-effective when compared to that of Osimertinib in the treatment of non-small cell lung cancer with EGFR mutation in Vietnam.